文献速递膀胱癌与上尿路尿路上皮癌

经皮肾造瘘管顺行给予丝裂霉素凝胶治疗上尿路尿路上皮癌:一项多机构回顾性队列研究

Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study.
PubMed 文献 · BJU Int · 2022-11-15

该多机构回顾性队列研究纳入2020至2022年间四家三级转诊中心经皮肾造瘘管顺行给予丝裂霉素凝胶的上尿路尿路上皮癌患者32例,评估安全性(按常见不良事件评价标准v5.0分级)。中位随访15.0个月,输尿管狭窄发生3例(9%),无肾功能损害和治疗相关死亡;29例完成诱导并接受初次疾病评估,其中17例(59%)无疾病证据。

要点

  • 经皮肾造瘘管顺行给予丝裂霉素凝胶,输尿管狭窄发生率低(3例,9%)。
  • 不良事件包括乏力(27%)、腰痛(19%)、尿路感染(12%)、脓毒症(8%)和血尿(8%)。
  • 29例完成诱导并评估,17例(59%)无疾病证据,中位随访13.0个月无复发。

核心结论

  • 经皮肾造瘘管给予丝裂霉素凝胶的输尿管狭窄发生率低,安全性良好,且无需全身麻醉。

研究设计与样本

  • 多机构回顾性队列研究,纳入2020至2022年间四家三级转诊中心经皮肾造瘘管顺行给予丝裂霉素凝胶的上尿路尿路上皮癌患者32例。

主要发现

  • 32例患者至少接受一剂丝裂霉素凝胶,29例完成诱导并接受初次疾病评估。
  • 诱导治疗前13例(41%)存在残留肿瘤。
  • 首次诱导治疗剂量后中位15.0个月,3例(9%)发生输尿管狭窄,均接受治疗且后续无复发或慢性狭窄。
  • 其他不良事件包括乏力(27%)、腰痛(19%)、尿路感染(12%)、脓毒症(8%)和血尿(8%)。
  • 随访期间无患者出现肾功能损害,无治疗相关死亡;17例(59%)在初次疾病评估时无疾病证据,诱导后中位随访13.0个月无复发。

关键数值与推荐

  • 安全性按常见不良事件评价标准(v5.0)分级。
  • 疾病负担通过输尿管镜下的初次疾病评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the safety profile of antegrade mitomycin gel instillation through a percutaneous nephrostomy tube (PCNT) for upper tract urothelial carcinoma (UTUC) with the aim of decreasing morbidity associated with therapy. PATIENTS AND METHODS: Patients undergoing antegrade administration of mitomycin gel via PCNT were retrospectively included for analysis from four tertiary referral centres between 2020 and 2022. The primary outcome was safety profile, as graded by Common Terminology Criteria for Adverse Events (v5.0). Post-therapy disease burden was assessed by primary disease evaluation (PDE) via ureteroscopy. RESULTS: Thirty-two patients received at least one dose of mitomycin gel via PCNT for UTUC, 29 of whom completed induction and underwent PDE. Thirteen patients (41%) had residual tumour present prior to induction therapy. At a median of 15.0 months following first dose of induction therapy, ureteric stenosis occurred in three patients (9%), all of whom were treated without later recurrence or chronic stenosis. Other adverse events included fatigue (27%), flank pain (19%), urinary tract infection (12%), sepsis (8%) and haematuria (8%). No patients had impaired renal function during follow-up and there were no treatment-related deaths. Seventeen patients (59%) had no evidence of disease at PDE and have not experienced recurrence at a median follow-up of 13.0 months post induction. CONCLUSIONS: Administration of mitomycin gel via a PCNT offers a low rate of ureteric stenosis, demonstrates a favourable safety profile, and is administered without general anaesthesia.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Rose KM, Narang G, Rosen G, et al. Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study. BJU Int. 2022. PMID: 36285629. doi:10.1111/bju.15925

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。